Standard BioTools (LAB) to Release Quarterly Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) will likely be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $20.8040 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Standard BioTools Stock Up 2.7%

Shares of Standard BioTools stock traded up $0.02 on Wednesday, hitting $0.82. 469,302 shares of the company were exchanged, compared to its average volume of 2,759,515. Standard BioTools has a 1-year low of $0.70 and a 1-year high of $1.72. The stock has a market capitalization of $318.54 million, a price-to-earnings ratio of 4.05 and a beta of 1.42. The company has a 50-day moving average price of $0.91 and a 200 day moving average price of $1.04.

Institutional Trading of Standard BioTools

Several institutional investors and hedge funds have recently made changes to their positions in LAB. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Standard BioTools in the 4th quarter valued at about $65,000. XTX Topco Ltd increased its holdings in shares of Standard BioTools by 1,492.3% in the 4th quarter. XTX Topco Ltd now owns 206,903 shares of the company’s stock valued at $265,000 after acquiring an additional 193,909 shares during the period. Millennium Management LLC boosted its stake in Standard BioTools by 133.0% during the 4th quarter. Millennium Management LLC now owns 3,387,428 shares of the company’s stock worth $4,336,000 after purchasing an additional 1,933,853 shares during the period. Mak Capital One LLC grew its position in Standard BioTools by 21.1% during the 4th quarter. Mak Capital One LLC now owns 19,288,158 shares of the company’s stock worth $24,689,000 after purchasing an additional 3,356,352 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Standard BioTools by 9.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 172,134 shares of the company’s stock worth $221,000 after purchasing an additional 14,592 shares during the last quarter. 53.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Standard BioTools from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Standard BioTools presently has an average rating of “Reduce” and an average target price of $1.35.

About Standard BioTools

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.